Study: NCT06484335

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VRC07-523LS
Description: VRC07-523LS (VRC-HIVMAB075-00-AB) is a recombinant human immunoglobulin G1 (IgG1) broadly neutralizing monoclonal antibody (bNAb) directed against the HIV-1 CD4 binding site

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: VRC07-523LS
Description: VRC07-523LS (VRC-HIVMAB075-00-AB) is a recombinant human immunoglobulin G1 (IgG1) broadly neutralizing monoclonal antibody (bNAb) directed against the HIV-1 CD4 binding site

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: VRC07-523LS
Description: VRC07-523LS (VRC-HIVMAB075-00-AB) is a recombinant human immunoglobulin G1 (IgG1) broadly neutralizing monoclonal antibody (bNAb) directed against the HIV-1 CD4 binding site

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PGDM1400LS
Description: PGDM1400LS is a recombinant human IgG1 bNAb targeted against the HIV-1 V2 apex epitope region.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PGDM1400LS
Description: PGDM1400LS is a recombinant human IgG1 bNAb targeted against the HIV-1 V2 apex epitope region.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: PGDM1400LS
Description: PGDM1400LS is a recombinant human IgG1 bNAb targeted against the HIV-1 V2 apex epitope region.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAdOx1.tHIVconsv1
Description: ChAdOx1.tHIVconsv1 is a replication-deficient virus expressing six conserved sub-protein regions of Gag and Pol (regions 1-6) of HIV-1 as one chimeric protein designated HIVconsv1.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: ChAdOx1.tHIVconsv1
Description: ChAdOx1.tHIVconsv1 is a replication-deficient virus expressing six conserved sub-protein regions of Gag and Pol (regions 1-6) of HIV-1 as one chimeric protein designated HIVconsv1.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ChAdOx1.HIVconsv62
Description: ChAdOx1.HIVconsv62 is a replication-deficient virus expressing six conserved sub-protein regions of Gag and Pol (regions 1-6) of HIV-1 as one chimeric protein designated HIVconsv62.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: ChAdOx1.HIVconsv62
Description: ChAdOx1.HIVconsv62 is a replication-deficient virus expressing six conserved sub-protein regions of Gag and Pol (regions 1-6) of HIV-1 as one chimeric protein designated HIVconsv62.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MVA.tHIVconsv4
Description: MVA.tHIVconsv4 is a recombinant, non-replicating Modified Vaccinia Ankara (MVA) virus expressing six conserved sub-protein regions of Gag and Pol (regions 1-6) of HIV-1 as one chimeric protein designated tHIVconsv4.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: MVA.tHIVconsv4
Description: MVA.tHIVconsv4 is a recombinant, non-replicating Modified Vaccinia Ankara (MVA) virus expressing six conserved sub-protein regions of Gag and Pol (regions 1-6) of HIV-1 as one chimeric protein designated tHIVconsv4.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: A244d11 gp120
Description: A244d11 gp120, consists of the gp120 envelope glycoprotein HIV-1 subtype CRF_01AE A244 derived from the CM244 CRF_01AE strain, with an 11 amino N-terminal deletion. It is a modification of the A244 rgp120 immunogen from the AIDSVAX®B/E vaccine.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: A244d11 gp120
Description: A244d11 gp120, consists of the gp120 envelope glycoprotein HIV-1 subtype CRF_01AE A244 derived from the CM244 CRF_01AE strain, with an 11 amino N-terminal deletion. It is a modification of the A244 rgp120 immunogen from the AIDSVAX®B/E vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ALFQ
Description: ALFQ (Army Liposome Formulation, ALF) is a liposomal adjuvant containing a synthetic

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: ALFQ
Description: ALFQ (Army Liposome Formulation, ALF) is a liposomal adjuvant containing a synthetic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline (0.9% sodium chloride for injection) will be used as a placebo.